STENOCARE (STENO) Investor Update summary

Company Overview and Market Presence

• Focuses on prescription-based medical cannabis, operating in six countries across Europe and Australia, with plans to enter Canada as a seventh market.

• Danish cultivation facility supports product development and export ambitions.

Funding, Capital Plan, and Warrant Transaction

• Announced an 18-month capital plan in May 2023 to raise up to DKK 29.7 million through three share issues.

• Currently conducting a TO2 warrant exercise, part of the capital plan, with the exercise period from June 10 to June 21, 2024.

• Subscription price for new shares is DKK 3.16, with TO2 Warrants tradable and offering a 30% discount.

• First share issue in June 2023 was oversubscribed at 127%, and the second via TO1 Warrants in December 2023 reached 76% subscription.

• Participation requires holding TO2 warrants and subscribing through a bank's corporate action process by June 21, 2024.

Use of New Capital

• About 33% of net proceeds will support working capital for financial stability ahead of break-even.

• Approximately 67% will be used to amortize short-term debt, strengthening the balance sheet.

• Funds raised will also support product launches, regulatory approvals, facility upgrades, and loan repayments.

• Financial flexibility is prioritized to support international expansion and adapt to evolving medical cannabis legislation.